- Astex Pharma presented 9/27 at Jefferies conference. Click here for calendar of other webcasts and catalysts with links to my notes and find more detailed company and pipeline info on ASTX research page.
- pipeline slide (see below) - programs listed in order or prioritization after merger
- focus on molecularly-targeted small molecules, primarily in oncology space
- HSP90 - phase 1 just about complete. we've seen very early indications of clinical activity, including 1 SD and 1 PR among 4 GIST patients
- Montigen - in process of forming new public spinout company (more info here).
- no questions asked...
0 Comments
Supergen will make the following presentaitons at ASCO (note I did not locate any presentations by its proposed merger partner Astex):
Saturday June 4th: Oral Presentation Abstract #5011 5:30 PM - 5:45 PM "A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC)." Daniela Matei, MD Monday June 6th: Poster Presentation Abstract #8530 "Final results of phase I/II study of decitabine (DAC) combined with temozolomide (TMZ) in metastatic melanoma (MM)." Jan H. Beumer, PhD, PharmD Monday June 6th: Oral Presentation Abstract #6504 10:45 AM - 11:00 AM "Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML." Xavier G. Thomas, MD, PhD Monday June 6th: Poster Presentation Abstract #6537 "A phase II study with decitabine, low-dose cytarabine and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia or acute myeloid leukemia in patients with significant comorbidities." James Butera, MD Monday June 6th: Poster Presentation Abstract #3074 "Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens." Kamalesh K. Sankhala, MD, MBBS |
Categories
All
Archives
January 2020
|